RBC Capital Reaffirms Their Buy Rating on IGM Biosciences (IGMS)
In a report released on November 8, Brian Abrahams from RBC Capital maintained a Buy rating on IGM Biosciences (IGMS – Research Report), ...
Biotech firm backs off its focus on oncology research
IGM Biosciences pivoted to autoimmune disease, reducing R&D expenses. The company reported a net loss of $61.4 million. CEO ...
IGM Biosciences Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Revenue exceeded analyst estimates by 113%. Earnings per share (EPS) missed analyst estimates by 24%. Looking ahead, revenue ...
Cautious Outlook for IGM Biosciences Amid Delayed Data and Financial Adjustments
Analyst Michael Ulz of Morgan Stanley maintained a Hold rating on IGM Biosciences (IGMS – Research Report), retaining the price target of ...
Yahoo Finance6d
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update
MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced ...